Hello, my name is Marlise Luskin. I'm a physician at Dana-Farber Cancer Institute in Boston, Massachusetts, and I take care of adults with leukemias, both acute and chronic leukemias. At ASH this year, I'm pleased to present the results from a investigator-initiated phase 1 trial combining venetoclax and inotuzumab. We're doing this trial because inotuzumab, which is a drug approved for the treatment of relapsed BALL, is an anti-CD22 antibody drug conjugate. This has been a drug that's been very useful for helping patients with leukemia that's come back after prior treatment. The response rates are quite high, which we're very pleased with and find this drug valuable. But the responses are not perfect. In some patients, the depth and durability, how long that treatment lasts, is not as good as we'd like. So our goal was to improve outcomes by combining that drug with another effective drug in ALL. We decided to combine it with a drug called venetoclax, which is a pill that helps target a pathway called BCL2 and helps make cells more vulnerable to chemotherapy. We combine these two drugs, and this abstract, this ASH reports on those outcomes. We demonstrated that the drugs could be given together in a convenient fashion and be given And our outcomes are encouraging with high response rates with a significant portion of patients able to bridge to allogeneic transplant, which was the goal for those patients for curative intent. So we're really excited about this regimen and we're excited to present to our colleagues and see this regimen develop further in other settings. If our videos have helped you in any way and you're able to, please consider making a donation to help us continue this important work. Your gift will go three times as far when we reach $500,000 by the end of the year. Every contribution, big or small, makes a difference, and we're deeply grateful for your support.
HealthTree • December 28, 2025